EyePoint, Inc. has grown revenue −58% a year over three years and −41% a year over five. Revenue growth, 3-year annual rate: −58% (Biotechnology median +17%). Revenue growth, 5-year rate: −41%, growth has slowed since the five-year average. Years of annual history on file: 16, FY2009 to FY2025, as filed.

EYPTEyePoint, Inc.

Healthcare

$3.40-74% 1Y

$3.40

$3.1552 weeks$18.85

Is it growing?

Watch

Growth is fading: revenue shrinking (−95% year on year) and operating margin narrowing (−11859.6 points).

2 to watch, 1 without data

Revenue trend−95% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −41% a year.

Margin direction−11859.6 points operating

Trailing-twelve-month operating margin, -12376.6% now against -517.0% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is EYPT growing?

EyePoint, Inc. has grown revenue −58% a year over three years and −41% a year over five.

−58%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −41%
Revenue growth, 5-year rate · −58% over three · growth has slowed since the five-year average
Years of annual history on file: 16
Years of annual history on file · FY2009 to FY2025, as filed

Details›